CEDA up 20% after first quarter report



RESULTS OF OPERATION

Comparison of Three Months Ended March 31, 2007 and March 31, 2006

Revenues increased by $1,738,824 or 129% in 2007 to $3,086,227 as compared to $1,347,403 in 2006, resulting in gross profit of $2,199,916 for 2007 as compared to gross profit of $853,652 in 2006. This was mainly attributable to the income generated from the training center, new programs, and advertising income. During 2006 and 2007, the Company has added several new programs for vocational studies and certification programs, which provides new source of income. Advertising income was increased as the result of the increased awareness of the Company\'s website, which resulted in more viewers coming to the Company\'s website, which enables the Company to increase its advertising income.

Cost of sales increased by $392,560 to $886,311 in 2007 as compared to $493,751 in 2006. Cost of sales as a percentage of sales decreased by 8% to 29% for 2007 as compared to 37% for 2006. The overall increase was primarily due to the increase of sales, which results from an increase in the cost of booklets and simulation tests to increase.

Gross profit margin increased by 8% for 2007 as compared to 2006. Gross profit margins vary from product to product depending on a number of factors including:
(a) cost of materials; (b) overall market demand and individual customer demand;
(c) cost of intellectual property rights; and (d) competitor pricing policies.

Selling expenses increased by $661,415 or 743% to $750,438 from $89,023 in 2006 due to the increase in agency fees associated with increased sales and advertising.

http://biz.yahoo.com/e/070516/ceda.ob10qsb.html

Ceda.ob: outlook

Last quarter they reported an loss of around 250.000 dollar. The quarters bevor that, they had an income of mor than 1 million each. So, I think the one time payment to original shareholders was about 1,5 million. They beat year 2006 estimates in revenue by 2 million, but failed income by 500.000.

My estimates are: 10-15 percent quarter to quarter revenue growth and income of 4 million in 2007.

So i´ll take an eps of around 0,07 cent.

With the current stock price ceda looks very cheap

What happend last quarter?

They make a loss in the fourth quarter, why?

What do you expect for this quarter in rev, income and eps

I have many free cash (:

Your list looks hot

good time to buy ceda.ob

Because of the next report around may 15th.

I´m looking for a double in revenue and income yoy.

Then ceda need some volume like 100k shares traded a day.

Hopefully we might see this in the next few days.

KSW anuall meeting next week

nice dip to add, next quarter will be big

KSW-first quarter results

KSW, Inc. (AMEX: KSW) today reports financial results for the first quarter of 2007.

Total revenue for the first quarter of 2007 increased by 14.1%, or $2,230,000, to $17,991,000 as compared to $15,761,000 for the first quarter of 2006. The Company reported net income of $723,000 for the first quarter of 2007 as compared to net income of $346,000 in the first quarter of 2006. This represents earnings per share of $0.12 per share (basic and diluted), for the first quarter of 2007 as compared to an earnings per share of $0.06 per share (basic and diluted), for the first quarter of 2006.

Included in the results of the first quarter 2007, are stock compensation expenses related to the exercising of stock options and the accounting standard SFAS-123(R). Excluding the effect of these stock compensation expenses, the Company earned $905,000, or $0.16 per share (basic) and $0.15 per share (diluted) for the first quarter of 2007, as compared to $0.10 per share (basic and diluted) for the first quarter of 2006.

As of March 31, 2007, the Company's backlog was approximately $108,000,000.

Silc- Great Earnings Report a few days ago

Great Chart
I´m in at $21 after earnings, looking for $26 next week.

KSW-Revenue Growth 44%

Earnings release mid-may

SFNN..

the ihub board is filled with pumpers but this stock is the real deal.. check out the fillings and recent PRs.

10K EPS for 2007 .02 cents per share... current price is .013


>>>> think about that for a second... 10QSB will be monster in 2 weeks.

Great idea for a board, China. I am going to go with APPA. Here is a snapshot:

Key Statistics and Ratios
Price & Volume
Recent Price $1.05 52 Week High $2.19 52 Week Low $0.8400 Average Daily Volume 803 Beta 0.17 Share Related Items
Market Capitalization $26.71 M Shares Outstanding 25.44 M Float 24.37 M Dividend Information
Yield 0.00% Annual Dividend $0.00 Payout Ratio (TTM) 0.00% Dividend Date <Unknown> Financial Strength (MRQ)
Quick Ratio 3.70 Current Ratio 3.90 Long Term Debt/Equity 0.00 Total Debt/Equity 0.00 Valuation Ratios
Price/Earnings (TTM) 5.00 Price/Sales (TTM) N/A Price/Book (MRQ) 2.23 Price/Cash Flow (TTM) 5.30 Per Share Data
Earnings (TTM) $0.21 Sales (TTM) $0.00 Book Value (MRQ) $0.47 Cash Flow (TTM) $0.20 Cash (MRQ) $0.09 Management Effectiveness (TTM)
Return on Equity N/A Return on Assets -27.40% Return on Investments -34.30% Profitability (TTM)
Gross Margin N/A Operating Margin <Unknown> Profit Margin N/A Effective Tax Rate <Unknown>

They are in a bit of trouble recently, and need to finance to get their new drug approved and on the market. Here is a bit of background on the company, and last, I'll end with the latest PR.
----------------------------------------
The Company is a specialty pharmaceutical company focused on the development of pharmaceutical products utilizing its proprietary polymer-based drug delivery systems. The Company's focus is the development and commercialization of bioerodible injectable and implantable systems under the trade name Biochronomer. Its business strategy is twofold: to develop selected proprietary products, funding them through the preliminary phases of regulatory review before entering into partnerships to share costs and to earn a share of future profits; and - to license its proprietary technologies to corporate partners after the successful completion of reimbursed feasibility studies to earn research and development fees, licensing fees, milestone payments and royalties. Bioerodible polymers are of increasing interest within the pharmaceutical and biotechnology community for use in both drug delivery applications and as devices. The Company has made progress in developing bioerodible polymers that potentially represent an improvement over existing drug delivery systems. During 2005, A.P. Pharma completed a Phase 2 human clinical trial using APF530, its lead product candidate for the prevention of both acute and delayed chemotherapy-induced nausea and vomiting in patients undergoing both moderately and highly emetogenic chemotherapy for cancer. APF530 contains the anti-nausea drug granisetron formulated with the Company's proprietary Biochronomer bioerodible drug delivery system. The Company's second Biochronomer product candidate is APF112 for the treatment of post-surgical pain. APF112 incorporates the well-known analgesic mepivacaine in its Biochronomer system. As part of the Company's strategy to protect its current products and to provide a foundation for future products, it has filed a number of United States patent applications on inventions relating to the composition of a variety of polymers, specific products, product groups, and processing technology. A.P. Pharma has a total of 19 issued United States patents and an additional 108 issued foreign patents. Currently, it has 42 pending patent applications worldwide. The Company relies on unpatented trade secrets and know-how to protect certain aspects of its production technologies. As of February 28, 2006, the Company had 36 full-time employees, 5 of whom hold PhDs.
---------------------------------------------

A.P. Pharma Files Registration Statement for a Common Stock Offering

REDWOOD CITY, Calif., Apr 05, 2007 (BUSINESS WIRE) -- A.P. Pharma, Inc. (APPA), a specialty pharmaceuticals company, announced today that it has filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission for a proposed public offering of up to $28,750,000 of its common stock. All of the shares in the proposed offering are being sold by the Company.

Proceeds from this offering are intended to be used for clinical development of APF530, the Company's lead product candidate; development and clinical testing of other candidates; and for working capital, capital expenditures and other general corporate purposes.

Merriman Curhan Ford & Co. will act as underwriter and book-running manager for the proposed offering. This offering will be made only by means of a prospectus. When available, copies of the prospectus relating to these securities may be obtained from: Merriman Curhan Ford & Co., 600 California Street, 9th Floor, San Francisco, CA 94108, Telephone 415-248-5600, Fax 415-248-5690.
---------------------------------

As soon as these shares hit, the price will go down, as there will be dilution. After the madness is over, look for a good entry point. This is a pretty good company that has been around, and if their product gets approved, will sell very nicely. One to accumulate.

Welcome To My Board !!!

I would like to see your picks...